⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7118799 | 0.82 | — | — | |
| SCHEMBL7118792 | 0.82 | — | — | |
| SCHEMBL23802878 | 0.79 | PLG (0.31) | — | |
| SCHEMBL19975105 | 0.79 | PLG (0.31) | — | |
| SCHEMBL29184159 | 0.79 | PLG (0.31) | — | |
| SCHEMBL10219095 | 0.79 | PLG (0.33) | — | |
| SCHEMBL4725538 | 0.79 | PLG (0.33) | — | |
| SCHEMBL4725540 | 0.79 | PLG (0.33) | — | |
| SCHEMBL16520322 | 0.79 | — | — | |
| SCHEMBL22482963 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230381321-A1 | CAMPTOTHECIN CONJUGATES | SEAGEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230257365-A1 | SMALL MOLECULE ANDROGEN RECEPTOR PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230233690-A1 | ANDROGEN RECEPTOR PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2023-07-27 | — | — | US | disclosed |
| US-20230159573-A1 | SMALL MOLECULE STAT PROTEIN DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| US-20230158154-A1 | CONJUGATES COMPRISING A PHOSPHORUS (V) AND A CAMPTOTHECIN MOIETY | TUBULIS GMBH (DE) | 2023-05-25 | — | — | US | disclosed |
| US-20230133671-A1 | SETD2 INHIBITORS AND RELATED METHODS AND USES, INCLUDING COMBINATION THERAPIES | Epizyme, Inc. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230036256-A1 | CAMPTOTHECIN CONJUGATES | SEAGEN INC. | 2023-02-02 | — | — | US | disclosed |
| US-20220033503-A1 | Anti PD-L1 Conjugates for Treating Tumors | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2022-02-03 | — | — | US | disclosed |
| US-20220023437-A1 | HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH, INC. (US) | 2022-01-27 | — | — | US | disclosed |
| US-20210402002-A1 | CONJUGATE | GLYKOS BIOMEDICAL OY (FI) | 2021-12-30 | — | — | US | disclosed |
| US-11116847-B2 | Methylene carbamate linkers for use with targeted-drug conjugates | SEAGEN INC. (US) | 2021-09-14 | — | — | US | disclosed |
| US-10981987-B2 | Humanized anti-CD79b antibodies and immunoconjugates and methods of use | GENENTECH, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-10894090-B2 | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins | AGENSYS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-RE48389-E1 | Antibody drug conjugates (ADC) that bind to 191P4D12 proteins | AGENSYS, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20200179527-A1 | COMPOUNDS FOR TARGETED IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2020-06-11 | — | — | US | disclosed |
| US-20180201679-A1 | HUMANIZED ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH INC (US) | 2018-07-19 | — | — | US | disclosed |
| US-20180177888-A1 | COMPOUNDS FOR TARGETED IMMUNOTHERAPY | SHANGHAI BIRDIE BIOTECH INC. (CN) | 2018-06-28 | — | — | US | disclosed |
| US-20170234883-A1 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | GENENTECH, INC. (US) | 2017-08-17 | — | — | US | disclosed |
| US-20170166635-A1 | CYSTEINE ENGINEERED ANTI-TENB2 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | GENENTECH INC (US) | 2017-06-15 | — | — | US | disclosed |